Review Article
[Retracted] Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review
Table 2
Anti-inflammatory effect, the antiapoptotic effects of noscapine.
| Effects | Type of study | Model | Cancer type | Dose/Conc | Mechanism | Years | Ref |
| Inducing apoptosis | In vivo | Blocking CDH17 gene in colon cancer SW480 cells | Colon cancer cells | 10 µmol/L | ↑Bax, ↓Bcl-2 and ↓Bcl-xL | 2017 | [135] | Antiproliferation | In vitro and in vivo | | Triple negative breast cancer | 100 mg/kg | Increase sensitivity to docetaxel | 2017 | [136] | Inducing apoptosis | In vivo | MCF7 cells | Breast cancer | | Progression in G2/M transition | 2021 | [137] | Inducing apoptosis | In vitro | The expression of apoptotic genes significantly increased | Endometriosis | 3 μg/mL | Inhibiting angiogenesis and nitric oxide | 2019 | [138] | Antineuroinflammation | In vivo | Parkinson’s disease | | 10 mg/kg | Enhancing the expression of mTOR and prevented apoptosis | 2021 | [139] | Inducing apoptosis | In vitro and in vivo | Human breast cancer cell lines MDA-MB-231 and MDA-MB-468 | Breast cancer | 50 mg/kg | Promoting effect on apoptosis-induced apoptosis in colon cancer cells via p53-dependent pathway reduces VEGF expression | 2019 | [140] | Anticancer | In vivo | LNCaP and PC-3 human prostate cancer cell lines | Human prostate cancer cell lines | 50 μM | ↓Bcl-2-↑Bax, and ↑Bax/Bcl-2 ratio | 2017 | [141] | Inducing apoptosis -tubulins | In vivo | MCF-7 and MDA-mb-231 | Breast cancer | 1.35 ± 0.2 μM | ↑ROS ↓tubulin assembly | 2020 | [142] | Tubulin | In situ | STD-NMR | | 0.6 μM | ↓tubulin assembly | 2020 | [143] | Inhibition of p-glycoprotein | In vivo | Human breast adenocarcinoma cell line MCF7 | Breast cancer | 45.4 ± 6.5 μM | ↓P-gp function | 2019 | [102] | Inducing apoptosis | In vivo | The human colon cancer cell lines HT29 and LoVo | Colon cancer cells | 75 μM | ↓PI3K/mTOR signalling-↓Warburg effect | 2020 | [56] | Inducing apoptosis | In vivo | U87 cells | Human glioblastoma cells | 46.8 µM | ↑apoptosis | 2019 | [144] | Antiangiogenic | In vivo | Human umbilical vein endothelial cells | Endothelial cells | 11.87 μM for Cl-noscapine, 6.9 μM for Br-noscapine, and 6.79 μM for folate-noscapine | Antiangiogenesis activity | 2018 | [116] |
|
|
STD-NMR: Saturation transfer difference (STD) Nuclear Magnetic Resonance (NMR). |